Unicycive Therapeutics Stock Forecast, Price & News

Unicycive Therapeutics (NASDAQ:UNCY) Frequently Asked Questions

Is Unicycive Therapeutics a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Unicycive Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Unicycive Therapeutics stock.
View analyst ratings for Unicycive Therapeutics or view top-rated stocks.

Are investors shorting Unicycive Therapeutics?

Unicycive Therapeutics saw a drop in short interest in November. As of November 15th, there was short interest totaling 70,700 shares, a drop of 34.9% from the October 31st total of 108,600 shares. Based on an average trading volume of 168,000 shares, the short-interest ratio is presently 0.4 days. Approximately 0.8% of the shares of the stock are sold short.
View Unicycive Therapeutics' Short Interest.

When is Unicycive Therapeutics' next earnings date?

Unicycive Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, February 10th 2022.
View our earnings forecast for Unicycive Therapeutics.

How were Unicycive Therapeutics' earnings last quarter?

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) announced its earnings results on Thursday, November, 11th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.11) by $0.26.
View Unicycive Therapeutics' earnings history.

What price target have analysts set for UNCY?

2 brokerages have issued twelve-month price targets for Unicycive Therapeutics' stock. Their forecasts range from $13.50 to $13.50. On average, they anticipate Unicycive Therapeutics' stock price to reach $13.50 in the next twelve months. This suggests a possible upside of 561.8% from the stock's current price.
View analysts' price targets for Unicycive Therapeutics or view top-rated stocks among Wall Street analysts.

Who are some of Unicycive Therapeutics' key competitors?

Some companies that are related to Unicycive Therapeutics include ContraFect (CFRX), Entasis Therapeutics (ETTX), Otonomy (OTIC), Concert Pharmaceuticals (CNCE), Tiziana Life Sciences (TLSA), Clever Leaves (CLVR), GT Biopharma (GTBP), scPharmaceuticals (SCPH), Tyme Technologies (TYME), Trevena (TRVN), Mereo BioPharma Group (MREO), IMV (IMV), Kala Pharmaceuticals (KALA), vTv Therapeutics (VTVT) and Adamis Pharmaceuticals (ADMP).
View all of UNCY's competitors.

When did Unicycive Therapeutics IPO?

(UNCY) raised $25 million in an initial public offering on Tuesday, July 13th 2021. The company issued 4,600,000 shares at $5.00-$6.00 per share. Roth Capital Partners acted as the underwriter for the IPO and EF Hutton (formerly Kingswood Capital Markets) was co-manager.

What is Unicycive Therapeutics' stock symbol?

Unicycive Therapeutics trades on the NASDAQ under the ticker symbol "UNCY."

When does Unicycive Therapeutics' lock-up period expire?

Unicycive Therapeutics' lock-up period expires on Monday, January 10th. Unicycive Therapeutics had issued 5,000,000 shares in its IPO on July 13th. The total size of the offering was $25,000,000 based on an initial share price of $5.00. After the expiration of Unicycive Therapeutics' lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company will be lifted.

Who are Unicycive Therapeutics' major shareholders?

Unicycive Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Board of Trustees of The Leland Stanford Junior University (1.71%), Geode Capital Management LLC (0.18%), Two Sigma Investments LP (0.18%), Tandem Capital Management Corp ADV (0.11%) and BlackRock Inc. (0.08%).

Which major investors are buying Unicycive Therapeutics stock?

UNCY stock was purchased by a variety of institutional investors in the last quarter, including Board of Trustees of The Leland Stanford Junior University, Geode Capital Management LLC, Two Sigma Investments LP, Tandem Capital Management Corp ADV, and BlackRock Inc..

How do I buy shares of Unicycive Therapeutics?

Shares of UNCY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Unicycive Therapeutics' stock price today?

One share of UNCY stock can currently be purchased for approximately $2.04.

How much money does Unicycive Therapeutics make?

Unicycive Therapeutics has a market capitalization of $30.54 million.

What is Unicycive Therapeutics' official website?

The official website for Unicycive Therapeutics is www.unicycive.com.

Where are Unicycive Therapeutics' headquarters?

Unicycive Therapeutics is headquartered at 5150 EL CAMINO REAL SUITE A-32, LOS ALTOS CA, 94022.

How can I contact Unicycive Therapeutics?

Unicycive Therapeutics' mailing address is 5150 EL CAMINO REAL SUITE A-32, LOS ALTOS CA, 94022. The company can be reached via email at [email protected].